Transient expression of Human papillomavirus type 16 L1 protein in Nicotiana benthamiana using an infectious tobamovirus vector

Virus Research

Volumn 120, Issue 1-2, 2006, Pages 91-96

  Varsani, Arvind ^a   Williamson, Anna Lise ^a,b   Stewart, Debbie ^a   Rybicki, Edward P ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

HPV 16; Papillomavirus; Plant expression; TMV vector; Vaccine; VLP

Indexed keywords

HUMAN PAPILLOMAVIRUS TYPE 16 L1 PROTEIN; PLANT EXTRACT; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VECTOR;

ARTICLE; CONFORMATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; NICOTIANA BENTHAMIANA; NONHUMAN; PLANT; PLANT LEAF; PLANT VIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; TOBACCO MOSAIC VIRUS; TOBAMOVIRUS; TRANSMISSION ELECTRON MICROSCOPY; VIRUS PARTICLE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; ANTIGENS, VIRAL; CAPSID PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENETIC VECTORS; NEUTRALIZATION TESTS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PLANT LEAVES; RECOMBINANT PROTEINS; TOBACCO; TOBACCO MOSAIC VIRUS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; NICOTIANA BENTHAMIANA; ORYCTOLAGUS CUNICULUS; TOBACCO MOSAIC VIRUS; TOBAMOVIRUS;

EID: 33745341751     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2006.01.022     Document Type: Article

References (32)

1. Awram P., Gardner R.C., Forster R.L., and Bellamy A.R. The potential of plant viral vectors and transgenic plants for subunit vaccine production. Adv. Virus Res. 58 (2002) 81-124
2. Biemelt S., Sonnewald U., Galmbacher P., Willmitzer L., and Muller M. Production of human papillomavirus type 16 virus-like particles in transgenic plants. J. Virol. 77 (2003) 9211-9220
3. Canizares M.C., Nicholson L., and Lomonossoff G.P. Use of viral vectors for vaccine production in plants. Immunol. Cell Biol. 83 (2005) 263-270
4. Christensen N.D., Cladel N.M., Reed C.A., Budgeon L.R., Embers M.E., Skulsky D.M., McClements W.L., Ludmerer S.W., and Jansen K.U. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types. Virology 291 (2001) 324-334
5. Christensen N.D., Dillner J., Eklund C., Carter J.J., Wipf G.C., Reed C.A., Cladel N.M., and Galloway D.A. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 223 (1996) 174-184
6. Clifford G.M., Smith J.S., Plummer M., Munoz N., and Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br. J. Cancer 88 (2003) 63-73
7. Combita A.L., Touze A., Bousarghin L., Christensen N.D., and Coursaget P. Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J. Virol. 76 (2002) 6480-6486
8. Fligge C., Giroglou T., Streeck R.E., and Sapp M. Induction of type-specific neutralizing antibodies by capsomeres of human papillomavirus type 33. Virology 283 (2001) 353-357
9. Giroglou T., Sapp M., Lane C., Fligge C., Christensen N.D., Streeck R.E., and Rose R.C. Immunological analyses of human papillomavirus capsids. Vaccine 19 (2001) 1783-1793
10. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., Zahaf T., Innis B., Naud P., De Carvalho N.S., Roteli-Martins C.M., Teixeira J., Blatter M.M., Korn A.P., Quint W., and Dubin G. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 (2004) 1757-1765
11. Huang Z., Elkin G., Maloney B.J., Beuhner N., Arntzen C.J., Thanavala Y., and Mason H.S. Virus-like particle expression and assembly in plants: hepatitis B and Norwalk viruses. Vaccine 23 (2005) 1851-1858
12. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., Chiacchierini L.M., and Jansen K.U. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347 (2002) 1645-1651
13. Liu H.L., Li W.S., Lei T., Zheng J., Zhang Z., Yan X.F., Wang Z.Z., Wang Y.L., and Si L.S. Expression of human papillomavirus type 16 L1 protein in transgenic tobacco plants. Acta Biochim. Biophys. Sin. (Shanghai) 37 (2005) 153-158
14. Mason H.S., and Arntzen C.J. Transgenic plants as vaccine production systems. Trends. Biotechnol. 13 (1995) 388-392
15. Mason H.S., Ball J.M., Shi J.J., Jiang X., Estes M.K., and Arntzen C.J. Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 5335-5340
16. McGarvey P.B., Hammond J., Dienelt M.M., Hooper D.C., Fu Z.F., Dietzschold B., Koprowski H., and Michaels F.H. Expression of the rabies virus glycoprotein in transgenic tomatoes. Biotechnology (N.Y.) 13 (1995) 1484-1487
17. Mechtcheriakova I.A., Eldarov M.A., Nicholson L., Shanks M., Skryabin K.G., and Lomonossoff G.P. The use of viral vectors to produce hepatitis B virus core particles in plants. J. Virol. Methods 131 (2006) 10-15
18. Rabindran S., and Dawson W. Assessment of recombinants that arise from the use of a TMV-based transient expression vector. Virology 284 (2001) 182-189
19. Richter L.J., Thanavala Y., Arntzen C.J., and Mason H.S. Production of hepatitis B surface antigen in transgenic plants for oral immunization. Nat. Biotechnol. 18 (2000) 1167-1171
20. Roden R.B., Armstrong A., Haderer P., Christensen N.D., Hubbert N.L., Lowy D.R., Schiller J.T., and Kirnbauer R. Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope. J. Virol. 71 (1997) 6247-6252
21. Rose R.C., Lane C., Wilson S., Suzich J.A., Rybicki E., and Williamson A.L. Oral vaccination of mice with human papillomavirus virus-like particles induces systemic virus-neutralizing antibodies. Vaccine 17 (1999) 2129-2135
22. Sanders G.D., and Taira A.V. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg. Infect. Dis. 9 (2003) 37-48
23. Shivprasad S., Pogue G.P., Lewandowski D.J., Hidalgo J., Donson J., Grill L.K., and Dawson W.O. Heterologous sequences greatly affect foreign gene expression in tobacco mosaic virus-based vectors. Virology 255 (1999) 312-323
24. Stanley M.A., Moore R.A., Nicholls P.K., Santos E.B., Thomsen L., Parry N., Walcott S., and Gough G. Intra-epithelial vaccination with COPV L1 DNA by particle-mediated DNA delivery protects against mucosal challenge with infectious COPV in beagle dogs. Vaccine 19 (2001) 2783-2792
25. Suzich J.A., Ghim S.J., Palmer-Hill F.J., White W.I., Tamura J.K., Bell J.A., Newsome J.A., Jenson A.B., and Schlegel R. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 11553-11557
26. Taira A.V., Neukermans C.P., and Sanders G.D. Evaluating human papillomavirus vaccination programs. Emerg. Infect. Dis. 10 (2004) 1915-1923
27. Varsani A., Williamson A.L., Rose R.C., Jaffer M., and Rybicki E.P. Expression of Human papillomavirus type 16 major capsid protein in transgenic Nicotiana tabacum cv. Xanthi. Arch. Virol. 148 (2003) 1771-1786
28. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., Snijders P.J., Peto J., Meijer C.J., and Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189 (1999) 12-19
29. Warzecha H., Mason H.S., Lane C., Tryggvesson A., Rybicki E., Williamson A.L., Clements J.D., and Rose R.C. Oral immunogenicity of human papillomavirus-like particles expressed in potato. J. Virol. 77 (2003) 8702-8711
30. White W.I., Wilson S.D., Palmer-Hill F.J., Woods R.M., Ghim S.-J., Hewitt L.A., Goldman D.M., Burke S.J., Jenson A.B., Koenig S., and Suzich J.A. Characterization of major neutralizing epitope on human papillomavirus type 16 L1. J. Virol. 73 (1999) 4882-4889
31. WHO, 1999. The current status of development of prophylactic vaccines against human papillomavirus infection. Report of a Technical Meeting, Geneva, 16-18 February 1999.
32. Wigdorovitz A., Perez Filgueira D.M., Robertson N., Carrillo C., Sadir A.M., Morris T.J., and Borca M.V. Protection of mice against challenge with foot and mouth disease virus (FMDV) by immunization with foliar extracts from plants infected with recombinant tobacco mosaic virus expressing the FMDV structural protein VP1. Virology 264 (1999) 85-91